<DOC>
	<DOC>NCT01576341</DOC>
	<brief_summary>The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney disease (CKD)</brief_summary>
	<brief_title>HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Main Adult male and female patients w or w/o dialysis treatment Stable i.v. or s.c. maintenance therapy with an EUapproved ESA treatment or ESA na√Øve. Adequate iron substitution Main History of Pure Red Cell Aplasia (PRCA) or antierythropoietin (EPO) antibodies Contraindications for ESA therapy Serum albumin &lt; 3.0 g/dL Immunocompromized patients (immunosuppressive treatment, chemotherapy) Hepatitis C infection on an active treatment or hepatitis B or human immunodeficiency virus (HIV) infection Systemic lupus erythematosus Symptomatic congestive heart failure, Unstable angina pectoris, or myocardial infarction within 6 months History of malignancy of any organ system within the last 5 years History of use of any nonEU approved ESA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Epoetin alfa, ESA, HX575, CKD</keyword>
</DOC>